Belite Bio's Financial Overview
SAN DIEGO, CA — Belite Bio, Inc (NASDAQ: BLTE) has made significant strides in the third quarter of 2025 towards enhancing treatment options for degenerative retinal diseases. The company reported its financial results for the quarter ending September 30, 2025, and shared crucial updates regarding ongoing clinical trials.
Clinical Trial Milestones Achieved
PHOENIX and DRAGON Trials
Belite Bio has successfully completed patient enrollment in the pivotal Phase 3 PHOENIX trial, targeting geographic atrophy (GA), with a total of 530 subjects. This key trial aims to assess the effectiveness of Tinlarebant, an oral therapy designed to reduce toxic vitamin A accumulation in the eye.
Additionally, the company has finalized the Phase 3 DRAGON trial for Stargardt disease (STGD). Results from this trial are highly anticipated and expected to be released in the fourth quarter of 2025.
Regulatory Advancements for Tinlarebant
Belite Bio received encouraging news from regulatory authorities. China's National Medical Products Administration (NMPA) has agreed to review the New Drug Application (NDA) for Tinlarebant with priority, based on interim findings from the DRAGON trial. Similarly, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Conditional Marketing Authorization application for Tinlarebant.
Financial Highlights This Quarter
Capital Raising Initiatives
The company secured significant funding in this quarter by completing a $15 million registered direct offering along with a $125 million private placement. This financial boost may total up to $165 million with the full exercise of accompanying warrants, strengthening Belite's position for upcoming regulatory and clinical milestones.
Expense Overview
Belite Bio's total operating expenses for the third quarter reached $23.0 million, a notable increase compared to $9.7 million in the same quarter of 2024. The increase is largely attributed to research and development costs connected to the DRAGON and PHOENIX trials.
General and administrative expenses also spiked to $12.7 million from $2.9 million reported in the previous year, emphasizing the importance of expanding operational capacities as the clinical development advances.
Future Prospects for Belite Bio
Final Data and Market Expectations
With the forthcoming final topline data for the DRAGON trial, Belite is optimistic about the potential for regulatory approval, which could pave the way for commercial launch. The clinical landscape for STGD and GA remains critical as effective treatment options are limited.
Continued Commitment to Innovation
Belite Bio's dedication to addressing unmet medical needs in the field of ophthalmology is reflected in its innovative drug candidate, Tinlarebant. The company's advances symbolize hope for patients affected by these challenging conditions.
About Belite Bio
Belite Bio is a clinical-stage drug development corporation committed to delivering groundbreaking therapies targeting degenerative retinal diseases and other metabolic conditions. The company remains focused on providing novel treatment options and advancing its lead candidate, Tinlarebant, through various phases of clinical testing.
Frequently Asked Questions
What are the main highlights from Belite Bio's third quarter report?
Significant achievements include completing enrollment in the Phase 3 PHOENIX trial and the successful finalization of the DRAGON trial, along with substantial funding raised.
How has Belite Bio's funding impacted its operations?
The financial support through direct offerings and private placements enhances Belite's capability to advance clinical trials and reach regulatory milestones.
What is the significance of the DRAGON trial for Belite Bio?
The DRAGON trial is pivotal for assessing the efficacy of Tinlarebant in treating Stargardt disease, and results from this trial are critical for future regulatory approvals.
How does the regulatory landscape look for Belite Bio's products?
Belite received positive feedback from both the NMPA and MHRA regarding the review of Tinlarebant, indicating progress toward obtaining necessary approvals.
What are the future goals for Belite Bio?
The company aims to finalize its clinical trials successfully, achieve regulatory approvals, and bring innovative therapies to market for patients with significant unmet needs.
